In combination w/ androgen deprivation therapy w/ or w/o androgen receptor (AR) pathway inhibition for the treatment of progressive prostate-specific membrane antigen (PSMA) +ve metastatic castration-resistant prostate cancer (mCRPC) in adults who have been treated w/ AR pathway inhibition & taxane-based chemotherapy.
IV Recommended treatment regimen: 7,400 MBq every 6 wk (±1 wk) for up to a total of 6 doses, unless there is disease progression or unacceptable toxicity.
Risk from radiation exposure. Risk of myelosuppression & renal toxicity. Perform lab tests (haematology, kidney/liver function) before & during treatment. Patients should remain well hydrated & urinate frequently before & after treatment administration. Contains up to 3.9 mmol (88.75 mg) Na per vial. Minor influence on ability to drive & use machines. Not recommended in patients w/ moderate to severe renal impairment w/ baseline CrCl <50 mL/min or ESRD. Has not been studied in patients w/ moderate or severe hepatic impairment. Not indicated for use in females. Potential to cause foetal harm when administered to a pregnant woman. Potential toxic effects on male gonads & spermatogenesis. Male patients are advised not to father a child & to use a condom for intercourse during treatment & for 14 wk after the last dose. No relevant use in paed population.
Sign Out
